AVEO Oncology has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive licence to investigate the potential of AVEO’s small molecule vascular endothelial growth factor(VEGF) tyrosine kinase inhibitor, tivozanib,outside of Asia for the potential treatment of non-oncologic diseases of the eye.

Under the terms of the agreement, Ophthotech is obligated to pay an upfront option fee of $500,000 to investigate tivozanib as a potential treatment for non-oncologic diseases of the eye.

During the option term, if Ophthotech elects to continue development of the ocular formulation of tivozanib after its initial analysis, AVEO is eligible to receive upto $8 million in milestone payments based upon the achievement of specified research, development and business goals.

Ophthotech has the exclusive option, exercisable at its sole discretion, to obtain additional development and commercialisation rights to tivozanib and products containing tivozanib for non-oncologic eye indications in territories outside Asia, subject to certain conditions, including outcomes of a proof of concept clinical trial and the negotiation of a definitive licence agreement.

If Ophthotech exercises its option, AVEO would receive an option exercise fee of $2 million and could also receive clinical and regulatory based milestone payments, of upto $50 million, sales based milestone payments of upto $45 million and royalties on product sales.

Ophthotech is responsible for all research and development activities and costs, and upon exercise of its option, further development and commercialisation activities and costs for tivozanibocular indications.

A percentage of all  upfront, milestone and royalty payments received by AVEO are due to Kyowa Hakko Kirin as a  sublicencing fee.

"This agreement is another example of our execution against AVEO’s key
strategic objective of advancing our pipeline assets through external resources and expertise," stated Tuan Ha-Ngoc, president and chief executive officer of AVEO.“We believe the unique properties of tivozanib make it an ideal VEGF inhibitor for potential ocular use, and we are encouraged by Ophthotech’s
interest in exploring this potential.This agreement could enable us to realise value for tivozanib an indication outside of cancer, while retaining oncology rights for further development through additional potential partnerships.”